The relationship between serum uric acid level and concentration of proangiogenic endothelial progenitor cells in chronic heart failure patients

Authors

  • A. A. Kremzer

DOI:

https://doi.org/10.14739/2409-2932.2017.2.103764

Keywords:

chronic heart failure, serum uric acid, circulating endothelial progenitor cells, predictive value of tests

Abstract

Serum uric acid (SUA) is considered as a marker of nature progression of chronic heart failure (CHF) mediated cardiovascular remodeling. Progression of CHF associates with declining of circulating endothelial progenitor cells (EPCs) in the peripheral circulation.

the objective of this study: to establish predictive relationship between the content of uric acid in the blood and the level of circulating endothelial progenitor cells in patients with CHF of ischemic origin.

Methods: The study population was structured retrospectively in 126 subjects (54 male), aged 48 to 62 years, with mild-to-severe ischemic CHFSUA level was measured by enzymatic methods, NT-pro-BNP level was examined by immunoelectrochemiluminesence method. EPCs were determined as CD 34+ cells by the flowcytometric technique using High-Definition Fluorescence Activated Cell Sorter methodology. All biomarkers were measured at baseline. The study was approved by an institutional review committee.

Results: Concentrations of SUA were distributed by quartiles (Me; IQR): QI=201,1 (190,6; 223,3) umol/l; QII=275,3 (232,0; 311,0) umol/l; QIII=358,0 (320,0; 390,0) mmol/l; and QIV=449,0 (400,0; 496,0) umol/l. We found an independent impact of SUA on counts of CD14+CD309+ EPCs (r=-0.388; P=0.001) and CD14+CD309+Tie2+ MPCs (r=-0.414; P=0.001), but on CD45+CD34+ EPCs (r=-0.214; P=0.22) and CD45-CD34+ MPCs (r=-0.16; P=0.16) did not.

Cox proportional adjusted Odds Ratios analyses for CD14+CD309+ and CD14+CD309+Tie2+ EPCs by SUA Quartiles (Q) has showed that high Q (Q3 and Q4) of SUA versus low Q (Q1 and Q2) associated with increased risk of depletion of both CD14+CD309+ and CD14+CD309+Tie2+ EPCs. The ROC analysis showed that there was the cut-off point for the SUA level with the best prognostic potential on the risk of decreasing EPCs in both models equal 315,0 umol/l.

Conclusion: Circulating level of proangiogenic EPCs phenotyped as CD14+CD309+ and CD14+CD309+Tie2+ is declined progressively depended on quartiles of SUA level in CHF subjects.

References

Hartupee, J., & Mann, D. L. (2013) Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. J. Cardiovasc. Transl. Res., 6(4), 485–492. doi: 10.1007/s12265-013-9467-y.

Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H. et al. (2013) Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur. J. Heart Fail., 16(1), 15–24. doi: 10.1093/eurjhf/hft132.

Kuo, C. F., See, L. C., Yu, K., Chou, I. J., Chiou, M. J., & Luo, S. F. (2013) Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. (Oxford), 52(1), 127–134. doi: 10.1093/rheumatology/kes223.

Berezin, A. E., & Kremzer, A. A. (2013) Serum uric Acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiol Res Pract., 2013, 129369.

Rehman, J., Li, J., Orschell, C. M., & March, K. L. (2003) Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation, 107, 1164–1169.

Trachtenberg, B. H., & Hare, J. M. (2009) Biomarkers of oxidative stress in heart failure. Heart Fail Clin., 5(4), 561–577. doi: 10.1016/j.hfc.2009.04.003.

Bakogiannis, C., Tousoulis, D., Androulakis, E., Briasoulis, A., Papageorgiou, N., Vogiatzi, G., et al. (2012) Circulating endothelial progenitor cells as biomarkers for prediction of cardiovascular outcomes. Curr. Med. Chem., 19(16), 2597–604. doi: 10.2174/092986712800492995.

McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J., 33, 1787–1847. doi: 10.1093/eurheartj/ehs104.

Tamariz, L., Harzand, A., Palacio, A., Verma, S., Jones, J., & Hare, J. (2011) Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail., 17(1), 25–30. doi: 10.1111/j.1751-7133.2011.00200.x.

Alcaíno, H., Greig, D., Castro, P., Verdejo, H., Mellado, R., García, L., et al. (2011) The role of uric acid in heart failure. Rev. Med. Chil., 139(4), 505–515. doi: /S0034-98872011000400014.

Downloads

How to Cite

1.
Kremzer AA. The relationship between serum uric acid level and concentration of proangiogenic endothelial progenitor cells in chronic heart failure patients. Current issues in pharmacy and medicine: science and practice [Internet]. 2017Jun.21 [cited 2024Dec.27];(2). Available from: http://pharmed.zsmu.edu.ua/article/view/103764

Issue

No. 2 (2017)

Section

Experimental and clinical pharmacology

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.     Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)